Early Phase 1 N=6 Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
Squamous Cell Carcinoma of the Oral Cavity
Primary: Area Under the Curve (AUC) for Matrine in Saliva — 4007.9 ng x h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 Pharmacokinetics of Ketamine in Infants and Children
The Pk of IV Ketamine in Children With Heart Disease
Primary: Total Clearance and Intercompartmental Clearance — 60.0; 70.8 L/h/70kg
Phase 2 N=59 Pharmacokinetics of Advantage Arrest in Children
Dental Caries
Primary: Predicted Peak Serum Silver Concentration (Cmax) — 17.8 ng/ml
Phase 2 N=143 Evaluate Safety, Efficacy and Pharmacokinetics
Metastatic Breast Cancer
Primary: Area Under the Concentration Time Curve at Steady State (AUCss) — 34400; 31800 ug*h/mL
N/A N=107 Pharmacokinetics of Daunorubicin in Young Patients With Cancer
Unspecified Childhood Solid Tumor, Protocol Specific
Primary: Population Estimates for Daunorubicin Hydrochloride Clearance — 116 L/m2/hr
Phase 3 N=13 A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
Pulmonary Arterial Hypertension
Primary: To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen…
Phase 4 N=60 Pharmacokinetics of Preoperative Vancomycin
Surgical Site Infection · Vancomycin
Primary: Pharmacokinetics Analysis: V˅c — 2.56; 1.14 L
Phase 3 N=30 Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery
Late Effects of Surgery · Staphylococcus Aureus · Surgical Site Infection
Primary: Mean Daptomycin Concentrations at 12, 18, 24, and 48 h — 22.7; 16.2; 12.0; 3.5 mcg/ml
Phase 1 N=16 Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Leukemia
Primary: Average Total Body Clearance (Calculated From Rate and Concentration) — 129 L/hr/m^2
Phase 1 N=24 Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution
Asthma
Primary: Area Under the Plasma Concentration-time Profile From Time 0 the Last Quantifiable Concentration (AUC0-last) With Dose Normalization — 658; 700; 716; 748 pg.h/mL…
Phase 3 N=31 Pharmacokinetic Comparison Of All FK-506 Formulations
Renal Failure
Primary: Evaluation of T(Max) for Envarsus XR, Astagraf XL and Prograf. — 5.91; 1.93; 1.48 hour
Phase 2 N=16 Pharmacokinetics of Advantage Arrest
Dental Caries
Primary: Observed Fluoride Urinary Recovery — 1.29 mg
Phase 1 N=22 Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
Acquired Immunodeficiency Syndrome
Primary: Plasma Lopinavir/Ritonavir Concentrations as Measured by the Area Under the Curve (AUC 0-12h). — 99599; 73603; 45146 ng.h/mL — p=<0.05
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Phase 4 N=12 Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) at Steady-State (After 3rd Dose) — 193.33; 165.70 mcg/mL
Phase 1 N=32 Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)
Acute Pain
Primary: Paracetamol Peak Plasma Concentration (Cmax) After Single Dose — 2181.04 ng/mL
Early Phase 1 N=7 Pharmacokinetics of Metronidazole Dermal Products
Bioequivalence
Primary: PK Parameters — 283; 341; 189 ng*h/mL
Phase 1 N=33 A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants
Healthy Participants
Primary: Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1 — 9.148; 18.18; 25.23; 38.32…
Phase 1 N=8 Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide — 17.56; 32.95 μg/mL
Phase 2 N=35 Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure
Heart Failure
Primary: C Max (Day 1, Dose 1) — 58; 243; 209 ng/mL
Phase 4 N=21 Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
Pompe Disease · Glycogen Storage Disease Type II (GSD II)
Primary: Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Alglucosidase Alfa — 204000; 307000 nanograms per milliliter (ng/mL)
Phase 1 N=6 A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
Hepatitis B Virus
Primary: Maximum Observed Plasma Concentration (Cmax) — 8.17 ng/mL
Phase 1 N=30 Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
Epilepsy
Primary: Maximum Drug Concentration (Cmax) — 9469; 9867; 15067; 17309 ng/mL
N/A N=1,113 Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
HIV Infections
Primary: PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs — 55.1; 43.50; 45.8; NA mg*hour/L — p=0.055
Phase 2 N=16 Pharmacokinetics of Advantage Anti-Caries Varnish
Dental Caries
Primary: Observed Iodine Tmax — 1.7 hours
Phase 2 N=15 Human Fibrinogen - Pharmacokinetics
Fibrinogen Deficiency
Primary: Maximum Clot Firmness (MCF) — 0; 8.9 millimeters — p=<0.0001
Phase 2 N=27 Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Change In Plasma PPi From Baseline To Pre-3rd Dose At Week 9 — -2.604; -3.797; -4.484 μM — p=<0.0001
Phase 4 N=56 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
Tinea Pedis · Tinea Cruris
Primary: Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose — 138262.2; 15890.1; 68634.2; 17213.9 h*pg/mL
Phase 1 N=16 Eletriptan Pharmacokinetics In Korean Males
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 291.3; 575.6; 1282.0; 1278.0 ng* hr/mL
Phase 3 N=38 Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases
Primary Immune Deficiency Disorders · Common Variable Immunodeficiency · X-linked Agammaglobulinaemia
Primary: Data (Derived From Absolute Concentration) Were Pooled With Historical Data and a Treatment Variable Defined (Subgam-VF or Gammaplex 5% IGIV). Outcome Measure Defined as…